A Phase 1 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 62nd largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 101st largest by enrollment of the 117 interventional ones that give a count, is one of 3 that started in 2020, is one of 40 in phase 1, and was the 2nd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
Drug: Placebo
Participants received 15 mg of tirzepatide QW by SC injection.
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Administered SC
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Sleep RQ
Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Weight (BW)
Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat-Free Mass
Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Body Fat Mass
Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Percentage of Body Fat Mass
The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Fasting Insulin Resistance
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18 during standardized mixed meal tolerance test
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
Time frame: Baseline, Week 18
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
Time frame: Baseline, Week 18
| Milestone | Placebo | 15 Milligram (mg) Tirzepatide |
|---|---|---|
| Started | 28 | 27 |
| Received at least one dose of study drug | 28 | 27 |
| Completed | 24 | 24 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
| kilocalories per day (kcal/day) | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) | -154.36 ± 19.69 | -134.68 ± 21.62 |
Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| kilocalories (kcal) | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal | -58.57 ± 82.29 | -914.51 ± 82.29 |
24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
| kcal/day | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE) | -296.85 ± 27.67 | -300.07 ± 30.44 |
Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| Ratio | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ) | 0.005 ± 0.005 | -0.030 ± 0.006 |
Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| ratio | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Sleep RQ | -0.001 ± 0.006 | -0,028 ± 0.006 |
RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| minute | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Duration of Periods With RQ<0.80 | 2.55 ± 43.97 | 254.44 ± 47.14 |
Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| gram/day | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Adjusted protein oxidation | -0.14 ± 1.23 | -7.00 ± 1.32 |
| Adjusted fat oxidation | -1.64 ± 2.15 | 12.83 ± 2.30 |
| Adjusted carbohydrate oxidation | 4.23 ± 4.24 | -22.42 ± 4.54 |
Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
| kilogram (kg) | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Body Weight (BW) | -8.26 ± 0.90 | -16.73 ± 0.92 |
Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| kg | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Body Fat-Free Mass | -1.64 ± 0.36 | -5.73 ± 0.36 |
Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| kg | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Body Fat Mass | -6.75 ± 0.65 | -11.83 ± 0.65 |
The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| Percentage | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Percentage of Body Fat Mass | -3.12 ± 0.36 | -4.26 ± 0.36 |
Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| millimole hour per liter (mmol.h/L) | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Triglyceride | -0.69 ± 0.27 | -2.52 ± 0.27 |
| VLDL cholesterol | -0.32 ± 0.12 | -1.16 ± 0.12 |
| HDL cholesterol | 0.20 ± 0.18 | -0.33 ± 0.18 |
| Free fatty acid | -0.09 ± 0.08 | 0.35 ± 0.08 |
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| index | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Fasting Insulin Resistance | -0.37 ± 0.12 | -0.34 ± 0.14 |
Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| index | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Postprandial Insulin Sensitivity | 1.43 ± 0.94 | 4.92 ± 0.94 |
Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
| millimolar.hour per liter (mmol.h/L) | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT | -1.73 ± 0.38 | -3.00 ± 0.38 |
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.
| percentage of glycosylated hemoglobin | Placebo | 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c) | -0.04 ± 0.04 | -0.40 ± 0.04 |
Collected over Baseline Through End of Safety Follow-up (Up to 22 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 0/28 (0%) | 19/28 (67.9%) |
| 15 mg Tirzepatide | 0/27 (0%) | 1/27 (3.7%) | 22/27 (81.5%) |
| Event | Placebo | 15 mg Tirzepatide |
|---|---|---|
| PancreatitisGastrointestinal disorders | 0/28 | 1/27 |
| CholelithiasisHepatobiliary disorders | 0/28 | 1/27 |
| Event | Placebo | 15 mg Tirzepatide |
|---|---|---|
| NauseaGastrointestinal disorders | 7/28 | 14/27 |
| ConstipationGastrointestinal disorders | 4/28 | 10/27 |
| Injection site reactionGeneral disorders | 0/28 | 10/27 |
| HeadacheNervous system disorders | 9/28 | 6/27 |
| VomitingGastrointestinal disorders | 3/28 | 7/27 |
| DiarrhoeaGastrointestinal disorders | 2/28 | 6/27 |
| DyspepsiaGastrointestinal disorders | 0/28 | 5/27 |
| Corona virus infectionInfections and infestations | 4/28 | 1/27 |
| Abdominal distensionGastrointestinal disorders | 1/28 | 3/27 |
| Urinary tract infectionInfections and infestations | 3/28 | 2/27 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | 15 mg Tirzepatide | Total |
|---|---|---|---|
| Mean | 48.1 ± 10.7 | 45.5 ± 9.8 | 46.8 ± 10.3 |
| Sex: Female, Male(Participants) | Placebo | 15 mg Tirzepatide | Total |
|---|---|---|---|
| Female | 24 | 22 | 46 |
| Male | 4 | 5 | 9 |
| Race (NIH/OMB)(Participants) | Placebo | 15 mg Tirzepatide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 11 | 23 |
| White | 15 | 14 | 29 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 15 mg Tirzepatide | Total |
|---|---|---|---|
| United States | 28 | 27 | 55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in May 2022, 22 months.
Results were first posted in Feb 2024, 1 year 8 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 22 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide